

## **First Patient Treated in Severe Stroke Study**

*Patient at risk for clinically significant brain swelling enrolled in study and treated with RP-1127.*

New York, NY, USA – May 31, 2011 – Remedy Pharmaceuticals, Inc. today announced that the GAMES-PILOT study of RP-1127 in severe stroke enrolled and treated its first patient on May 26, 2011.

GAMES-PILOT is a multi-center, prospective, open label, Phase 2a trial of RP-1127 in patients with a severe ischemic stroke who are likely to experience clinically significant brain swelling, termed malignant infarction. Malignant infarction is the syndrome of a large stroke causing progressive edema and tissue swelling that compromises arterial inflow to surrounding tissues, culminating in further ischemic damage, enlargement of the infarct, herniation, and death.

The study is currently enrolling at the University of Maryland Medical Center. More centers are expected to be added in the coming months. It is anticipated that the information gained in GAMES-PILOT will allow a much needed, randomized, double-blinded study to be designed for this patient population.

"We are delighted to have enrolled the first patient in the GAMES-PILOT study," says Sven Jacobson, Chief Executive Officer of Remedy. "This is a significant milestone for Remedy as it represents the first time a stroke patient has been given RP-1127. Initial indications are that the patient is responding well to treatment."

Detailed information for this study is available at:  
<http://clinicaltrials.gov/ct2/show/NCT01268683>

### **About RP-1127**

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

### **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)

